Roche-Spark deal faces FTC Republicans who overruled Democrats on BMS-Celgene
Roche’s acquisition of Spark Therapeutics is pending before a Federal Trade Commission that was starkly divided along party lines in a recent pharma deal that the Republican majority was willing to...To view the full article, register now.
Already a subscriber? Click here to view full article